Eagle Pharmaceuticals, Inc. · OTC:EGRX

Eagle Pharmaceuticals — Investor Presentation (September 2023)

20 slides from Eagle Pharmaceuticals's investor presentation, Sep 7, 2023

  1. Slide 1: Company Overview September 2023

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Company Overview September 2023

  2. Slide 2: Forward-Looking Statements

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95, as amended, and other securities law All statements other than statements of h

  3. Slide 3: A Diversified Pharmaceutical Company with Significant Opportunities for Growth

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 3 Eagle Pharmaceuticals: A Diversified Pharmaceutical Company with Significant Opportunities for Growth Substantial potential for further expansion Maintaining market share for bendamustine franchise Share of the commercial U.S. pemetrexed mark

  4. Slide 4: Eagle Pharmaceuticals: Strong Financial Position

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 4 Eagle Pharmaceuticals: Strong Financial Position Q2 2023 revenue of $64.6M and adjusted non - GAAP EBITDA of $20.7M † Gross margin of 74% and adjusted non - GAAP gross margin of 83% * † Oncology gross margin of 80% and adjusted non - GAAP gro

  5. Slide 5: EA-114 Product Candidate Provides Exciting Growth Opportunity; Eagle Plans to File NDA in 2024

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 5 EA - 114 Product Candidate Provides Exciting Growth Opportunity; Eagle Plans to File NDA in 2024 1. IQVIA SMART – US Edition Monthly. ● Estrogen receptor antagonist used in the treatment of metastatic breast cancer in post - menopausal women

  6. Slide 6: Earnings Timeline – Actuals and Guidance

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 6 6 Earnings Timeline – Actuals and Guidance 2020 2021 2022 Previous 2023E Range Revised 2023E Range 2 Adjusted EBITDA (US$M) 1 $64.7 $28.2 $132.1 $74.0 - $80.0 $78.0 - $84.0 Diluted Adjusted Non - GAAP EPS 1 $3.54 $1.68 $7.79 $4.20 - $4.53 $4.

  7. Slide 7: Oncology & Acute Care Contribution

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 7 Oncology & Acute Care Contribution (US$M) 1. Adjusted non - GAAP EBITDA, adjusted non - GAAP Gross Profit, adjusted non - GAAP R&D expense and adjusted non - GAAP SG&A expense are non - GAAP financial measures. For descriptions and reconcilia

  8. Slide 8: Eagle Growth Continues with More Diversified Revenue Streams

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 8 8 Eagle Growth Continues with More Diversified Revenue Streams 2023 Expectations 21% 16% 15% 8% 19% 20% 57% 55% 79% 84% 85% 92% 81% 80% 43% 45% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2016 2017 2018 2019 2020 2021 2022 1H2023 Other Revenu

  9. Slide 9: Barhemsys and Byfavo Momentum Continues

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 9 Growth primarily driven by Eagle’s experienced commercial team and access in the hospital space An estimated 19,000 patients 1 were dosed with Barhemsys or Byfavo during the second quarter of 2023 275 health care facilities purchased the prod

  10. Slide 10: Eagle's Business Development Strategy and Select Capital Spend

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 10 Eagle’s Business Development Strategy and Select Capital Spend Value OpEx Size Portfolio x Pursuing accretive acquisition opportunities x Leverage infrastructure x Opportunity for synergies / expense reductions x Potentially a ble to finance

  11. Slide 11: Eagle Product Portfolio Is Supported by Commercial Team

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 11 Eagle Product Portfolio Is Supported by 80 - Person Commercial Team RYANODEX ® For treatment of malignant hyperthermia BARHEMSYS ® For prevention of PONV*, and treatment of PONV in patients who received antiemetic prophylaxis with an agent o

  12. Slide 12: CAL02 Has the Potential to Elevate the SOC for SCABP

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 12 CAL02 Has the Potential to Elevate the SOC for SCABP W ithout Contributing to Antibiotic Resistance ● CAL02 1 is a novel first - in - class broad - spectrum anti - virulence agent being developed for the treatment of severe community - acqui

  13. Slide 13: ENA-001: An NCE with a Unique Mechanism of Action for Acute Respiratory Depression

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 13 ENA - 001: An NCE with a Unique Mechanism of Action for Acute Respiratory Depression ● ENA - 001 1 is an investigational new chemical entity being developed by Enalare as an agnostic respiratory stimulant for multiple patient populations exp

  14. Slide 14: Financial Appendix

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 14 14 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Financial Appendix

  15. Slide 15: Non-GAAP Financial Measures

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 15 Non - GAAP Financial Measures In addition to financial information prepared in accordance with U.S. GAAP, this presentation also contains non - GAAP financial m easures, including adjusted non - GAAP net income, adjusted non - GAAP EBITDA, a

  16. Slide 16: Reconciliation of GAAP Net Income to Adjusted Non-GAAP EBITDA

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 16 16 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Three Months Six Months Ended Ended 2022 2021 2020 Net income (loss) - GAAP 5,164$ 10,914$ 35,642$ (8,627)$ 11,989$ Add back: Interest expense, net of interest income 1,253 2,557 3,7

  17. Slide 17: Reconciliation of GAAP Net Income to Adjusted Non-GAAP Net Income

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 17 17 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Three Months Six Months Ended Ended 2022 2021 2020 Net income (loss) - GAAP 5,164$ 10,914$ 35,642$ (8,627)$ 11,989$ Adjustments: Cost of product revenues: Amortization expense 5,459

  18. Slide 18: Reconciliation of GAAP Oncology Gross Profit to Adjusted Non-GAAP

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 18 18 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Three Months Six Months Ended Ended Revenue: PEMFEXY TM 19,400$ 42,348$ BELRAPZO® 6,848 13,198 BENDEKA® 3,780 6,174 TREAKISYM 728 2,083 Oncology product sales, net 30,756$ 63,803$ BE

  19. Slide 19: Reconciliation of GAAP R&D and SG&A to Non-GAAP

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 19 19 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2023 2022 2023 2022 Research and development - GAAP 9,833$ 11,437$ 19,105$ 17,545$ Add back: Stock-based compensation expense 527 601 1,214 1,244 Depreciation expense 32 44 62 92 Sev

  20. Slide 20: Thank You!

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 20 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Thank You!

Eagle Pharmaceuticals — Investor Presentation (September 2023) on 6ix